Sentences with phrase «treatment of acute lymphoblastic leukemia»

The changes included reductions in the use and dose of radiation therapy and chemotherapy drugs called anthracyclines for treatment of acute lymphoblastic leukemia (ALL), Hodgkin lymphoma and Wilms tumor, a cancer of the kidneys.

This study included 68 childhood cancer survivors who had received cranial irradiation, intrathecal chemotherapy or both for treatment of acute lymphoblastic leukemia (ALL) or brain tumors.

Not exact matches

In March, the U.S. Food and Drug Administration (FDA) approved BLINCYTO for the treatment of adults and children with B - cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1 percent.

Current treatments for acute lymphoblastic leukemia (ALL), an aggressive form of blood cancer, include conventional chemotherapy drugs that inhibit DNA synthesis.

Noelle Frey, MD, an assistant professor of Hematology - Oncology, will present results in 27 adult patients with acute lymphoblastic leukemia (ALL), identifying an optimal dose and infusion regimen that should improve treatment response while reducing potential for side effects.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

The FDA approves Blincyto (blinatumomab) for use in the treatment of B cell acute lymphoblastic leukemia (ALL).

Herbert OettgenCRI CONNECTIONCVC MEMBERSCIENTIFIC ADVISOR reports the first treatment of patients with acute lymphoblastic leukemia with L - asparaginase.

In 2014, the FDA approved Amgen's BLINCYTO ® (blinatumumab), the first BiTE ® therapy to receive FDA approval, for the treatment of Philadelphia chromosome - negative relapsed or refractory B - cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.

Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the drugs that received the FDA's stamp of approval in 2017.

Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B - cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with relapsed or refractory DLBCL.

A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.

Introduction: The level of minimal residual disease (MRD) in marrow predicts outcome and guides treatment in childhood acute lymphoblastic leukemia (ALL) but accurate prediction depends on accurate measurement.

Lead study author Dr. Daniel Lacorazza noted that «acute lymphoblastic leukemia is a type of cancer of the white blood cells common in children... there is about an 80 percent cure rate, but some children don't respond to treatment.